3Sasso FC, Carbonara O, Persico M, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebocontrolled crossover study. Diabetes Care, 2002, 25:1909 - 1913.
4Malmqvist K, Ohman KP, Lind L, et al. Long-term effects of irbesartan and atenolol on the rennin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol(SILVHIA). J Cardiovasc Pharmacol, 2003, 42:719 - 726.
5Brunner HR. The new angiotensin Ⅱ receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens, 1997, 10(12 Pt 2):311S - 317S.
6Zanchetti A. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents. J Hypertens, 1997, 15(Suppl): S21-25.
7Simon TA, Gelarden RT, Freitag SA, et al. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol, 1998, 82:179- 182.
8MARKHAM A,APENCER CM,JARVIS B.Irbesartan:an updated review of its use in cardiovascular disorders[J].Drugs,2000,59(5):1187-1206.
9BURNIER M.Angiotensin Ⅱ type 1 receptor blockers[J].Circulation,2001,103(6):904-912.
10RIBSTEIN J,PICARD A,ARMAGNAC C,et al.Inhibition of the acute effects of angiotensin Ⅱ by the receptor antagonist irbesartan in normotensive men[J].J Cardiovasc Pharmacol,2001,37(4):449-460.
